Strides Pharma Consolidates European Business-to-Business Operations in Switzerland
- Market proximity of Strides Pharma International AG, based in Zug, Switzerland, opens the way for rapid technology transfer and innovation within the European market
- Oren Weininger, longstanding leader at Fairmed Healthcare, heads the business as CEO and Chairman of the Board
Zug, Switzerland. Strides Pharma Science Limited, globally recognized as a leading pharmaceutical company operating across 100 countries and headquartered in Bangalore, India, is consolidating its European business through Strides Pharma International AG, based in Zug, Switzerland.
Strides Pharma specializes in the development and manufacturing of IP-led niche finished dosage formulations. With over three decades of research and development expertise, Strides Pharma continuously develops and delivers products with innovative and improved technologies at competitive prices. Notably, Strides Pharma is among the world's largest manufacturers of Ibuprofen and Macrogol in various forms. Their unique range of drug delivery technologies opens up versatile and lucrative opportunities within the ever-evolving target markets.
The partner-centric in-licensing portfolio of over 250 formulations is consolidated in synergICE as a one-stop shop. It includes generics, sterile injectables and value-added products, Women´s Health hormones, lyophilized orally dissolving tablets and end-to-end biopharmaceutical CDMO services.
Oren Weininger, newly appointed Chairman of the Board, stated, “With this strengthened European B2B presence, we can respond faster to our customers’ needs and provide flexible, innovative solutions, and interesting generic portfolio, including comprehensive support in supply chain & quality management and regulatory processes by Strides Pharma International and the EU GMP-site in Hamburg, Germany.”
Key Markets are Central and Southern Europe (especially Germany), Scandinavia, Benelux and the Visegrád countries.
For further information, please visit: www.fair-med.com/newsroom
Contact Agency What About Now, Andreas Schöpf
as@whataboutnow.de Tel. +49 160 90723690
Following his roles at Dexcel Pharma and Kamedis, Oren Weininger took the position of CEO at Fairmed Healthcare AG in 2014 and subsequently became owner in 2018. Strides Pharma, after a period of successful partnership, invested in the company in 2019, further bolstering leading Fairmed Healthcare product lines. In addition to being appointed Chairman of the Board of Strides Pharma International AG, Weininger continues to lead Fairmed Healthcare GmbH in Hamburg.
Strides Pharma Science Limited, headquartered in Bangalore, India, was incorporated in 1990. The company has a global manufacturing footprint with eight facilities spread across four continents and a strong presence in 100 countries. Strides Pharma is a key active pharmaceutical ingredient manufacturer and producer of various products; every fourth Ibuprofen tablet on the global market today is supplied by Strides Pharma.
Images
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
FEV develops AI-supported driver monitoring system CogniSafe9.1.2025 11:00:00 CET | Pressmeddelande
Aachen – FEV, a leading global innovation driver for the mobility of tomorrow, presents CogniSafe, a state-of-the-art Driver Monitoring System (DMS) that significantly increases road safety. The system uses advanced technologies such as deep learning and computer vision to monitor driver conditions such as distraction, fatigue and inattention in real time and under even the most challenging conditions.
Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer9.1.2025 10:25:56 CET | Press Release
Aachen, Germany, 09 January 2025 – Grünenthal announced today that Prof. Dr. Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025. Uli Brödl has more than 15 years of industry experience. He joins Grünenthal from Boehringer Ingelheim, where he served as Corporate Senior Vice President, Head of Global Clinical Development & Operations, and member of Boehringer Ingelheim's Venture Fund Investment Committee. In his most recent role, he oversaw end-to-end clinical development and operations activities across therapeutic areas and worked at the interface of R&D, Commercial, and Market Access functions. He has a proven track record of bringing innovative medicines to patients, including Empagliflozin, an oral anti-diabetic medicine. Earlier in his career, Uli Brödl led Boehringer Ingelheim's Canadian medical organisation and gained extensive market experience. In parallel, he founded and co-chaired the BI Can
175 years of Heidelberger Druckmaschinen: Company starts anniversary year with growth strategy8.1.2025 13:11:11 CET | Press Release
Growth strategy: medium-term sales potential of more than € 300 million Growth drivers in the core business: packaging, digital printing Software and lifecycle business Industrial business: focus on further expansion 175 years: the company has been shaping the printing industry for decades with technological innovations, quality and reliability Numerous anniversary activities throughout the year
Assessing risks from pharmaceutical residues: How the APRIORA project is helping communities to improve drinking water quality7.1.2025 08:16:33 CET | Press Release
As part of the EU-funded APRIORA project, drug residues are being analysed. Scientists from the University of Rostock are taking water samples in all weathers. The aim is to use innovative approaches to improve wastewater treatment in Europe.
SNP expands partnership with SAP7.1.2025 08:07:10 CET | Press Release
Long-standing partnership as strong foundation for extended collaboration Expanded cooperation in global RISE with SAP transformation projects Joint initiative to develop data migration and conversion scenarios for public cloud solutions
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom